? Duke Center for AIDS Research (Overall) The principal mission of the Duke Center for AIDS Research (CFAR) is to establish and grow comprehensive infrastructure support for a research environment that will effectively promote collaboration, coordination, and innovation throughout the Duke HIV/AIDS research community and across the national CFAR network. As evidenced by the growth in our NIH-Funded Research Base that now qualifies us as a Tier 2 CFAR, this competitive renewal application represents an evolution that builds upon our accomplishments and lessons learned during the previous funding cycles, taking advantage of the synergies established among our Core components. A solid basis is formed by our highly successful Pilot Grant mechanism, aimed primarily at Early Stage Investigators, and our equally successful faculty recruitment efforts, both of which have facilitated greater gender and racial diversity. The driving force behind all of our evolving support services is a highly active and effective Strategic Planning process, led by our Executive Committee (EC), with valuable input from both our advisory committees and our intramural Strategic Partners. This highly iterative process has identified five Specific Aims to guide the CFAR's growth and evolution over the next 5 years: 1) Provide comprehensive infrastructure support to all intramural HIV/AIDS investigators aimed at expanding the robust program of inter- disciplinary, collaborative HIV research that addresses NIH Research priorities. 2) Continue development of a pipeline of next generation HIV/AIDS investigators through strong support of Early Stage Investigators and engagement of established investigators from outside the field of HIV/AIDS research. 3) Foster critical synergies through Core-Core interactions and engagement of new and existing Strategic Partnerships. 4) Expand the relevance, reach, and impact of HIV/AIDS research by implementing and supporting community engagement and outreach. 5) Further enhance and support collaborative activities throughout the global network of CFARs. Support services will be enhanced by increased institutional support from Duke's School of Medicine and Department of Surgery. Through our Strategic Planning process, we have identified eight priority areas that represent opportunities for further development during the next funding cycle. These include: 1) the `Southern HIV Epidemic'; 2) HIV Co-Morbidities, Co-Infections, and Complications; 3) Latency and Eradication; 4) Health Disparities; 5) Vaccine Design and Evaluation; 6) Mental Health and Substance Abuse; 7) the HIV Organ Policy Equity (HOPE) Act; and 8) Emerging Infections. Finally, to ensure the continued high-quality support for intramural HIV/AIDS investigators, the EC has formulated a Leadership Transition Plan, vetted by the institution, in which Dr. Georgia Tomaras and Dr. Susanna Naggie will become Director and Co-Director, respectively. The CFAR looks forward to developing and exploring these timely opportunities within Duke and across the CFAR network throughout the next funding cycle.

Public Health Relevance

? Overall The Duke Center for AIDS Research (CFAR) provides comprehensive infrastructure support to basic, translational, and clinical investigators conducting HIV/AIDS research. Maintaining strategic alignment with the National CFAR Mission Statement and the NIH Strategic Plan for HIV and HIV-Related Research, Duke CFAR will continue to advance toward our goals of HIV prevention and improving outcomes for people with HIV/AIDS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI064518-16
Application #
9991039
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Refsland, Eric William
Project Start
2005-04-01
Project End
2025-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
16
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Duke University
Department
Surgery
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Ferrari, Guido (2018) Tandem bispecific broadly neutralizing antibody - a novel approach to HIV-1 treatment. J Clin Invest 128:2189-2191
Dai, Joanne; Luftig, Micah A (2018) Intracellular BH3 Profiling Reveals Shifts in Antiapoptotic Dependency in Human B Cell Maturation and Mitogen-Stimulated Proliferation. J Immunol 200:1727-1736
Gichane, Margaret W; Sullivan, Kristen A; Shayo, Aisa M et al. (2018) Caregiver role in HIV medication adherence among HIV-infected orphans in Tanzania. AIDS Care 30:701-705
Ramadhani, Habib O; Muiruri, Charles; Maro, Venance P et al. (2018) Patient-Initiated Repackaging of Antiretroviral Therapy, Viral Suppression and Drug Resistance. AIDS Behav 22:1671-1678
Kelly, Matthew S; Surette, Michael G; Smieja, Marek et al. (2018) Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana. Pediatr Infect Dis J 37:1176-1183
Ramos, Julia V; Mmbaga, Blandina T; Turner, Elizabeth L et al. (2018) Modality of Primary HIV Disclosure and Association with Mental Health, Stigma, and Antiretroviral Therapy Adherence in Tanzanian Youth Living with HIV. AIDS Patient Care STDS 32:31-37
Saunders, Kevin O; Santra, Sampa; Parks, Robert et al. (2018) Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. J Virol 92:
Sikkema, Kathleen J; Choi, Karmel W; Robertson, Corne et al. (2018) Development of a coping intervention to improve traumatic stress and HIV care engagement among South African women with sexual trauma histories. Eval Program Plann 68:148-156
Watt, Melissa H; Cichowitz, Cody; Kisigo, Godfrey et al. (2018) Predictors of postpartum HIV care engagement for women enrolled in prevention of mother-to-child transmission (PMTCT) programs in Tanzania. AIDS Care :1-12
Itell, Hannah L; McGuire, Erin P; Muresan, Petronella et al. (2018) Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines. Vaccine 36:5600-5608

Showing the most recent 10 out of 488 publications